AUTHORS
Colleen A. Kelly, MD, Eva Robinson, MPH2, Edie Weller, PhD3, Callie Fry4, McKenzie Griffin, MBS5, Sunyu Kang, BS, BA6, Rahela Aziz-Bose, MD, MPH7, Leanne Duhaney, MD, MPH8, Kristine Karvonen, MD, MS9, Puja J. Umaretiya, MD, MS10, Natasha M. Archer, MD, MPH11, Kira Bona, MD, MPH12
AFFILIATIONS
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
4 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States
6 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States
7 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
8 Boston Children’s Hospital, Boston, Massachusetts, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 University of Texas Southwestern Medical Center, Dallas, United States
11 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
12 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Introduction: Sickle cell disease (SCD) affects 100,000 Americans and results in organ dysfunction, poor quality of life, and early death. Disease management is complex and often unpredictable; unplanned hospital admissions (e.g. for pain, fever, acute chest syndrome, stroke) impact work and school attendance, and result in lost income and direct and indirect out-of-pocket costs. Household material hardship ([HMH], unmet basic needs of food, housing, transportation, or utilities) is a concrete measure of financial toxicity, and prevalent in pediatric SCD (Kelly, PBC, 2026). Previous studies have qualitatively described the financial burden of disease management on families with pediatric SCD (Long, PBC, 2023) and quantified the association between HMH and emergency department reliance (Power-Hays, PBC, 2020). Whether hospital admissions are associated with HMH has not been quantified; we sought to characterize this association in a pediatric SCD cohort.
Methods: We conducted a secondary analysis of a cross-sectional, single-center study of children with SCD aged 2 to <18 years receiving care at Boston Children’s Hospital between 2024-2025. Foreign national patients and those with history of bone marrow transplant or gene therapy were excluded. Parents/guardians completed a 54-item quantitative survey of demographics, household structure, HMH, language, means-tested governmental benefits participation, and travel time to hospital. Clinical characteristics including genotype and hospital admissions for the year preceding survey administration were abstracted from the medical record. The primary outcome was HMH, modeled as both binary present (at least 1 domain: food, housing, utilities or transportation insecurity) vs absent (0 domains), as well as ordinal (0-4 domains). The primary exposure was hospital admissions in the year prior to survey administration, dichotomized as 0-1 admissions versus >2 admissions to reflect common thresholds for SCD disease severity, including trial eligibility criteria for gene therapy (≥2 severe vaso-occlusive episodes per year, the leading cause of hospitalization in this population). Cohort characteristics were summarized with descriptive statistics. Generalized logistic regression models assessed the association between HMH and admissions, adjusting for covariates (sex, age, genotype, travel time to hospital).
Results: Among 100 participants enrolled from 2024-2025, 96 (96%) completed the survey in 4 languages and 94 (98%) were evaluable for the primary outcome of HMH. Median age was 8 years, 68% had HbSS, 51% female, 60% Black, 28% Hispanic, 71% with only public insurance, and 56% living in a single-parent household; 64% lived >30-minutes from the hospital. At the household-level, 63% reported at least one HMH domain over the prior 12-months including utility (46%), food (45%), housing (43%) and transportation (17%) insecurities. Forty-nine percent of participants reported >2 HMH domains. A majority of children (76%) had 0-1 admissions in the past year. Means-tested benefits participation was: Supplemental Nutrition Assistance Program (44%), housing assistance (26%), and energy assistance (15%).
After adjusting for covariates, children with >2 admissions in the past year had a 3.3-fold higher odds of any HMH compared to others (OR = 3.3, 95% CI: 1.1–11.7, p = 0.047). In the ordinal model, patients with >2 hospital admissions had 2.7 times higher odds of having more severe HMH (OR = 2.7, 95% CI: 1.1–6.7, p = 0.034) relative to those with <2 hospital admissions.
Conclusion: Among children with SCD at a quaternary center, >2 hospital admissions in a year was associated with significantly higher odds of HMH, a concrete measure of financial toxicity. This matters for two reasons: HMH is associated with worse SCD outcomes, including disease-related complications (Sonenklar, PBC, 2025), and HMH independently predicts decreased family-reported ability to pursue transformative therapies such as gene therapy (Kelly, PBC, 2026). These data highlight an opportunity for care delivery interventions that target financial toxicity arising from acute care utilization. This opportunity is especially urgent as gene therapy is intended for patients with the most frequent acute care utilization—the same population at high risk for HMH and thus less equipped to navigate the logistical and financial demands such therapy requires.
DISCLOSURES
Callie Fry: No relevant conflicts of interest to declare.